Triple-Neg Breast Cancer

LitAlert ~~ GeneLit.com

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Aziz HA, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Karim KA, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Eldin NB, Elghazawy H.
Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, Li X, Hou W, Bao D, Ren L, Yang J, Wang S, Qiu Y, Zhou F, Liu Z, Zhu S, Zhang L, Qing T, Wang Y, Yu Y, Wu J, Hu X, Shi L.
Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.

A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
Wu R, Adachi K, Koyama Y, Orimoto K, Okazaki M, Asaoka M, Teraoka S, Ueda A, Miyahara K, Kawate T, Kaise H, Yamada K, Sato E, Ishikawa T.
J Surg Case Rep. 2021 Apr 14;2021(4):rjab018. doi: 10.1093/jscr/rjab018.

Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.
Atci MM, Geredeli Ç, Ay S, Sakin A, Ertürk B, Seçmeler S, Arici S, Çekin R, Yasar N, Can O, Cihan S, Gümüs M.
Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346.

High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
Evans G, van Veen EM, Byers HJ, Evans SJ, Burghel GJ, Woodward ER, Harkness EF, Eccles DM, Greville-Haygate SL, Ellingford JM, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.
J Med Genet. 2021 Mar 23:jmedgenet-2020-107347. doi: 10.1136/jmedgenet-2020-107347. Epub ahead of print.

Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
NPJ Breast Cancer. 2021 Mar 22;7:29. doi: 10.1038/s41523-021-00240-w. eCollection 2021.

Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.
Di Leone A, Fragomeni SM, Scardina L, Ionta L, Mulè A, Magno S, Terribile D, Masetti R, Franceschini G.
Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1910-1915. doi: 10.26355/eurrev_202102_25087.

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.

Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.

Molecular analyses of triple-negative breast cancer in the young and elderly.
Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.

Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
Liu M, Xie F, Liu M, Zhang Y, Wang S.
Breast Cancer Res Treat. 2021 Feb 9. doi: 10.1007/s10549-021-06104-y. Epub ahead of print.

DNA damage response inhibitors: An avenue for TNBC treatment.
Jin J, Tao Z, Cao J, Li T, Hu X.
Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.